Head-To-Head Survey: Amneal Pharmaceuticals (NASDAQ:AMRX) and Indivior (OTCMKTS:INVVY)

Indivior (OTCMKTS:INVVY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Risk and Volatility

Indivior has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Valuation and Earnings

This table compares Indivior and Amneal Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
Amneal Pharmaceuticals	$3.02 billion	2.17	$72.06 million	$0.49	41.80

Indivior has higher earnings, but lower revenue than Amneal Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Indivior and Amneal Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	0	1	0	3.00
Amneal Pharmaceuticals	1	0	9	0	2.80

Indivior currently has a consensus target price of $50.00, indicating a potential upside of 128.88%. Amneal Pharmaceuticals has a consensus target price of $21.25, indicating a potential upside of 3.76%. Given Indivior’s stronger consensus rating and higher probable upside, equities analysts clearly believe Indivior is more favorable than Amneal Pharmaceuticals.

Profitability

This table compares Indivior and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Institutional and Insider Ownership

0.1% of Indivior shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Indivior on 8 of the 14 factors compared between the two stocks.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.